Key Highlights
• Proteome Sciences LSE:PRM declined 14.86% on 21 September 2026, according to the market snapshot.
• The fall comes only days after the company released its H1 2026 results, giving investors fresh information about revenue, cash resources, costs and the pace of its commercial expansion.
• H1 Revenue was £1.87 million, broadly unchanged from £1.86 million a year earlier.
• Proteomics services revenue declined to £0.89 million, while TMT reagent sales and royalties increased to £0.98 million.
• Gross Profit improved to £0.44 million, while the operating loss narrowed to £1.24 million and the loss before tax reduced to £1.70 million.
• Cash resources stood at £1.10 million at 30 June 2026, compared with £0.78 million at the end of December 2025.
• The company recently secured another significant clinical contract connected with its chemoproteomics platform, with samples expected to start arriving later in 2026.
Why Is Proteome Sciences LSE:PRM in Focus Today?
Proteome Sciences has attracted renewed attention following a combination of fresh financial results and several developments around its targeted proteomics and chemoproteomics activities.
The 14.86% decline on 21 September 2026 comes after the company reported its six-month results on 16 September. The numbers showed relatively stable revenue but continued losses, meaning investors are assessing whether the company's expanding pipeline of clinical contracts can translate into stronger revenue and cash generation.
The company generated £1.87 million of revenue during H1 2026, only slightly above the £1.86 million recorded during H1 2025. However, the composition of revenue changed significantly, with TMT reagent sales and royalties providing a larger contribution while proteomics services revenue declined.
This mixed performance is an important part of the latest market reaction.
Why Did Proteome Sciences LSE:PRM Fall 14.86% on 21 September 2026?
The 14.86% fall follows a period in which investors have been weighing the company's continuing losses against its longer-term growth opportunities.
Although gross profit improved and operating costs were reduced, Proteome Sciences remains loss-making. Its H1 loss before tax was £1.70 million, compared with £2.07 million in H1 2025, while the loss for the period narrowed to £1.40 million from £2.14 million.
The market is therefore focused not simply on whether losses are narrowing, but on when the company's growing contract pipeline can generate sufficient revenue to support a more sustainable financial profile.
The latest decline also follows a significant fall in the share price over the broader 2026 period. Market data showed PRM trading around 1.27p on 21 September, compared with a 52-week range extending from approximately 1.20p to 4.40p.
What Were Proteome Sciences' Latest H1 2026 Results?
Proteome Sciences reported H1 revenue of £1.87 million, compared with £1.86 million in the corresponding period of 2025.
Proteomics services revenue fell 17% to £0.89 million from £1.07 million. However, TMT reagent sales and royalties rose to £0.98 million from £0.79 million.
Within that figure, TMT and TMTpro reagent sales increased significantly, while Royalty income was lower than the prior-year period.
Gross profit increased from £0.32 million to £0.44 million, helped by the changing revenue mix and tighter cost control.
Administrative and cost-of-sales expenses also declined, with total cost of sales and administrative expenses falling to £3.11 million from £3.48 million.
The result was a reduction in the operating loss from £1.62 million to £1.24 million.
Why Is the Chemoproteomics Pipeline Important for LSE:PRM?
Chemoproteomics is becoming an important growth area for Proteome Sciences because it extends the company's capabilities into drug discovery and clinical development.
On 15 September 2026, the company confirmed another significant clinical contract connected with its chemoproteomics platform. The project is being developed to comply with Good Clinical Laboratory Practice requirements and will be undertaken at its Frankfurt laboratory.
Importantly, this represented the third contract connected with the same protein for Phase 1 and Phase 2 Clinical Trials being conducted globally. Samples are expected to start shipping later in 2026.
This contract provides investors with evidence that the company's newer targeted and chemoproteomics capabilities are attracting commercial demand.
Can New Contracts Improve Proteome Sciences' Growth Profile?
Management remains focused on expanding its service revenues through newer technology platforms.
The company highlighted its 96plex, 105plex and DXT tags, together with targeted mass spectrometry and chemoproteomics workflows, as potential longer-term revenue drivers.
Management said it expects full-year 2026 services revenue to show a significant increase from 2025, supported by its order book. It also expects TMT revenues to recover during the second half of 2026.
The key issue for investors is whether those expectations translate into measurable revenue growth during H2.
What Is the Latest Cash Position at Proteome Sciences?
Cash resources stood at £1.10 million at 30 June 2026, compared with £0.78 million at 31 December 2025.
Operating cash flow remained negative at £0.43 million during H1, although this was an improvement from the £0.90 million outflow recorded during H1 2025.
This means Liquidity remains an important consideration for LSE:PRM.
The improvement in Operating Cash Flow and higher period-end cash balance provide useful context, but the company continues to operate with a substantial loss and negative operating cash flow.
Investors are therefore likely to monitor the relationship between new contract wins, revenue growth, operating expenditure and cash consumption.
What Are Investors Watching Next for Proteome Sciences LSE:PRM?
The main areas of attention include:
• H2 2026 services revenue
• Conversion of the existing order book into revenue
• New chemoproteomics contracts
• TMT and TMTpro sales
• Royalty income
• Cash consumption
• Operating-cost control
• Development of 96plex and 105plex capabilities
• Adoption of targeted mass spectrometry
• Progress of clinical projects
The company is also expanding its board's financial and strategic experience, with Helen Spice appointed as an independent non-executive director in September 2026.
What Could Drive the Next Move in LSE:PRM?
The next major share-price catalyst could come from evidence that the company's newer technology platforms are producing faster revenue growth.
A stronger second half, additional clinical contracts or improving TMT sales could provide further evidence of commercial traction.
Conversely, continued weak services revenue, persistent losses or faster cash consumption could maintain pressure on the shares.
The balance between these factors is particularly important because Proteome Sciences remains a small-cap healthcare technology company with a relatively low Market Capitalisation and a wide recent trading range.
What Is the Outlook for Proteome Sciences LSE:PRM?
The 14.86% decline on 21 September 2026 places the focus firmly on whether Proteome Sciences can convert its expanding technology and contract pipeline into stronger financial performance.
The H1 numbers showed mixed trends: revenue was broadly flat, services revenue declined, but TMT sales improved, gross profit increased, operating costs fell and the statutory loss narrowed.
At the same time, the company has recently secured another significant clinical chemoproteomics contract and remains confident about full-year services revenue growth.
For investors following LSE:PRM, the key evidence will come from H2 revenue delivery, new contract wins, TMT recovery, cash generation and the commercial adoption of its targeted and chemoproteomics platforms.






Please wait processing your request...